These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2199835)

  • 21. Medicare retiree drug subsidy compliance considerations.
    Pudlowski E
    Benefits Q; 2007; 23(1):21-7. PubMed ID: 17444082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Responding with a united voice to the Conditions of Coverage!
    VanBuskirk S
    Nephrol Nurs J; 2005; 32(3):266-7. PubMed ID: 16035469
    [No Abstract]   [Full Text] [Related]  

  • 23. Medicare and Medicaid programs; establishment of Chapter V for OIG regulations--HHS. Final rule.
    Fed Regist; 1986 Sep; 51(189):34764-86. PubMed ID: 10301242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HCFA, Stark eye Medicare ESRD expenditures.
    Koska MT
    Hospitals; 1988 May; 62(10):84. PubMed ID: 3283025
    [No Abstract]   [Full Text] [Related]  

  • 25. Re-engineering the ESRD Program amid Medicare reform.
    Neumann ME
    Nephrol News Issues; 2005 Jan; 19(2):40-1. PubMed ID: 15717573
    [No Abstract]   [Full Text] [Related]  

  • 26. Billing Medicare for investigational devices: what's OK, what's not.
    Gardner JR
    Healthc Financ Manage; 1997 Mar; 51(3):50-4. PubMed ID: 10165439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HCFA: failing to acknowledge the unique characteristics of the ESRD patient.
    Kanter A; Nidetz M
    Nephrol News Issues; 1990 Feb; 4(2):23-6, 31. PubMed ID: 2320135
    [No Abstract]   [Full Text] [Related]  

  • 28. Medicare and state health care programs: fraud and abuse; amendments to OIG exclusion and CMP authorities resulting from the Medicare and Medicaid Patient and Program Protection Act--Office of Inspector General (OIG), HHS. Final rule.
    Fed Regist; 1993 Jul; 58(145):40752-3. PubMed ID: 10127885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OIG investigations and physicians' rights.
    Barton HM
    Tex Med; 1989 Feb; 85(2):68-71. PubMed ID: 2648638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The stage is set for disease management and ESRD: can it succeed?
    Coutts LR; Neumann ME
    Nephrol News Issues; 1998 May; 12(5 Suppl):8. PubMed ID: 9652290
    [No Abstract]   [Full Text] [Related]  

  • 31. The Medicare secondary payer program: Part I.
    Breskin W
    Med Interface; 1994 Jun; 7(6):137-8, 140. PubMed ID: 10171896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. OIG report claims HCFA overpaid $54 million in 1991 for IDPN therapy.
    Knapp CJ
    Nephrol News Issues; 1993 Jul; 7(7):9-10, 14. PubMed ID: 8336804
    [No Abstract]   [Full Text] [Related]  

  • 33. Consolidated billing and compliance program--Part 2.
    Stahl DA
    Nurs Manage; 1998 Jun; 29(6):12-5. PubMed ID: 9807420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In a bundling era, finding a fair price for ESRD services.
    Sullivan JD
    Nephrol News Issues; 2007 Mar; 21(4):37, 39-40. PubMed ID: 17393926
    [No Abstract]   [Full Text] [Related]  

  • 35. GAO report cites sloppy work in HCFA audits of ESRD facilities.
    Neumann ME
    Nephrol News Issues; 1993 Jul; 7(7):11, 18. PubMed ID: 8336800
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of the Office of Health Technology Assessment in Medicare coverage decisions.
    Marshall JE; Carter ED
    J Health Care Technol; 1986; 3(2):75-8. PubMed ID: 10301219
    [No Abstract]   [Full Text] [Related]  

  • 37. Medicare and Medicaid statistical supplement, 1996. U.S. Department of Health and Human Services, Health Care Financing Administration.
    Health Care Financ Rev Stat Suppl; 1996; ():1-472. PubMed ID: 10162839
    [No Abstract]   [Full Text] [Related]  

  • 38. End stage renal disease.
    Greer J
    Health Care Financ Rev Annu Suppl; 1992; ():199-205. PubMed ID: 10131707
    [No Abstract]   [Full Text] [Related]  

  • 39. Caring for ESRD patients.
    Andriote JM
    Healthplan; 1998; 39(4):33-5. PubMed ID: 10351321
    [No Abstract]   [Full Text] [Related]  

  • 40. Spending controls cited as reasons for decline in health care cost hikes.
    Capitation Manag Rep; 2005 Apr; 12(4):44-5, 37. PubMed ID: 15913209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.